Galmed Pharmaceuticals Ltd.

Informe acción NasdaqCM:GLMD

Capitalización de mercado: US$4.3m

Salud financiera de hoja de balance de Galmed Pharmaceuticals

Salud financiera controles de criterios 6/6

Galmed Pharmaceuticals tiene un patrimonio de los accionistas total de $18.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $21.0M y $2.5M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$17.14m
PatrimonioUS$18.44m
Total pasivoUS$2.51m
Activos totalesUS$20.95m

Actualizaciones recientes sobre salud financiera

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 06
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Recent updates

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 06
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Galmed GAAP EPS of -$0.15 beats by $0.09

Aug 04

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 15
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Oct 02
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

May 20
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

Galmed gets greenlight for late-stage Aramchol NASH trial in China

May 03

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

Feb 04
What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Dec 06
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Galmed EPS misses by $0.02

Nov 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($17.7M) de GLMD superan a sus pasivos a corto plazo ($2.5M).

Pasivo a largo plazo: GLMD no tiene pasivos a largo plazo.


Historial y análisis de deuda-patrimonio

Nivel de deuda: GLMD está libre de deudas.

Reducción de la deuda: GLMD no ha tenido ninguna deuda en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: GLMD tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: GLMD dispone de suficiente cash runway para 2.1 años si el flujo de caja libre sigue creciendo a tasas históricas de 4.6% cada año.


Descubre empresas con salud financiera